{
    "ticker": "CLNNW",
    "name": "Clene Nanomedicine, Inc.",
    "description": "Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of neurodegenerative diseases. Founded in 2014 and headquartered in Salt Lake City, Utah, Clene's proprietary nanotechnology platform leverages unique nanocrystal formulations that are designed to modulate biological processes at the cellular level. The company's lead product candidates, CNM-Au8 and CNM-Ag8, are being developed for conditions such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). These therapies aim to restore mitochondrial function and improve neuronal health, addressing significant unmet needs in the field of neurology. Clene is committed to advancing science through rigorous clinical trials and collaboration with leading experts in the field. The company's mission is to transform the treatment landscape for patients suffering from progressive neurodegenerative conditions, ultimately enhancing their quality of life. Clene's innovative approach has garnered attention from investors and stakeholders, positioning the company as a key player in the biopharmaceutical industry.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Salt Lake City, Utah, USA",
    "founded": "2014",
    "website": "https://clenenanomedicine.com",
    "ceo": "Rob Etherington",
    "social_media": {
        "twitter": "https://twitter.com/CleneNanomed",
        "linkedin": "https://www.linkedin.com/company/clene-nanomedicine/"
    },
    "investor_relations": "https://ir.clenenanomedicine.com",
    "key_executives": [
        {
            "name": "Rob Etherington",
            "position": "CEO"
        },
        {
            "name": "David G. Pritchard",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "CNM-Au8",
                "CNM-Ag8"
            ]
        }
    ],
    "seo": {
        "meta_title": "Clene Nanomedicine, Inc. | Innovative Therapies for Neurodegenerative Diseases",
        "meta_description": "Explore Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on novel therapies for neurodegenerative diseases using unique nanotechnology.",
        "keywords": [
            "Clene Nanomedicine",
            "CNM-Au8",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "Pharmaceuticals",
            "ALS",
            "Multiple Sclerosis"
        ]
    },
    "faq": [
        {
            "question": "What is Clene Nanomedicine known for?",
            "answer": "Clene Nanomedicine is known for developing novel therapies for neurodegenerative diseases using nanotechnology."
        },
        {
            "question": "Who is the CEO of Clene Nanomedicine?",
            "answer": "Rob Etherington is the CEO of Clene Nanomedicine, Inc."
        },
        {
            "question": "Where is Clene Nanomedicine headquartered?",
            "answer": "Clene Nanomedicine is headquartered in Salt Lake City, Utah, USA."
        },
        {
            "question": "What are Clene's main products?",
            "answer": "Clene's main product candidates include CNM-Au8 and CNM-Ag8."
        },
        {
            "question": "When was Clene Nanomedicine founded?",
            "answer": "Clene Nanomedicine was founded in 2014."
        }
    ],
    "competitors": [
        "AVXL",
        "SAVA",
        "BTAI",
        "PTGX"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "GILD"
    ]
}